share_log

RNAZ Stock Alert: The Breast Cancer Study News Sending TransCode Therapeutics Soaring Today

RNAZ Stock Alert: The Breast Cancer Study News Sending TransCode Therapeutics Soaring Today

RNAZ股票警报:乳腺癌研究消息使转码治疗药物今天飙升
InvestorPlace ·  2021/09/23 12:48

TransCode Therapeutics (NASDAQ:RNAZ) stock is rocketing higher on Thursday as investors react to positive news from a breast cancer study.

代码转换治疗学(纳斯达克:RNAZ)周四,随着投资者对一项乳腺癌研究的积极消息做出反应,股价飙升。

Source: Bukhta Yurii / Shutterstock.com

来源:Bukhta Yurii/Shutterstock.com

According to a press release from the company, preclinical trial data for TTX-MC138 shows that it could be an effective treatment of breast cancer. TTX-MC138 is an RNA therapeutics treatment in development from the company.

根据该公司的一份新闻稿,TTX-MC138的临床前试验数据表明,它可能是一种有效的乳腺癌治疗方法。TTX-MC138是该公司正在开发的RNA疗法。

Results from the preclinical study were published in Cancer Nanotechnology. It’s under the title “Radiolabeling and PET-MRI microdosing of the experimental cancer therapeutic, MN-anti-miR10b, demonstrates delivery to metastic lesions in a murine model of metastatic breast cancer.”

临床前研究的结果发表在癌症纳米技术。它的标题是“实验性癌症治疗药物MN-anti-miR10b的放射标记和PET-MRI微剂量,证明了在转移性乳腺癌的小鼠模型中,MN-anti-miR10b可以传递到转移的病变中。”

Michael Dudley, CEO of TransCode Therapeutics, said this in the release sending RNAZ stock higher today.

转码治疗公司首席执行官迈克尔·达德利在新闻稿中说,这推动RNAZ股价今天走高。

‘For TransCode, we believe this study further confirms the pharmacokinetic profile of TTX-MC138, supporting the viability of our platform for delivery of RNA-based therapy to metastatic solid tumors. Our preclinical data further suggest the therapeutic potential of TTX-MC138, and we look forward to our Phase 0 study which has the potential to establish clinical proof-of-concept for this therapy.”

在代码转换方面,我们相信这项研究进一步证实了TTX-MC138的药代动力学特征,支持了我们为转移性实体肿瘤提供基于RNA的治疗的平台的可行性。我们的临床前数据进一步表明了TTX-MC138的治疗潜力,我们期待着我们的0期研究,它有可能为这种疗法建立临床概念验证。“

So what does TransCode Therapeutics plan to do next? The company says it will file an exploratory investigational new drug application for TTX-MC138 in the first quarter of 2022. The goal is to use this for support of a Phase 0 study of its potential breast cancer treatment.

那么转码治疗公司下一步计划做什么呢?该公司表示,将在2022年第一季度为TTX-MC138提交探索性研究新药申请。我们的目标是利用这一点来支持对其潜在乳腺癌治疗的0期研究。

RNAZ stock is seeing heavy trading on today’s news. As of this writing, more than 147 million shares of the stock have changed hands. To put that in perspective, the company’s daily average trading volume is closer to 1.1 million shares.

受今日新闻影响,RNAZ股票交易量很大。截至撰写本文时,该股已有超过1.47亿股易手。相比之下,该公司的日均成交量接近110万股。

RNAZ stock was up 91.4% as of Thursday afternoon.

截至周四下午,RNAZ股价上涨了91.4%。

We’ve got more of the latest stock market news investors need to know about below!

下面是投资者需要了解的更多最新股市新闻!

InvestorPlace offers deep dives into the stock market daily to assist traders. Today’s no different with us covering what thas shares of Plug Power (NASDAQ:PLUG), Novavax (NASDAQ:NVAX), and Roku (NASDAQ:ROKU) on the move. You can get all those details from the following links!

InvestorPlace提供每日深入股市的服务,以帮助交易员。今天的节目和我们分享的内容没有什么不同插头电源(纳斯达克:插头), 诺华(纳斯达克:NVAX),以及罗库(纳斯达克:罗库)移动中。您可以从以下链接获取所有这些详细信息!

More Thursday Stock Market News

更多周四股市新闻

On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.

在出版之日,威廉·怀特没有(直接或间接)持有本文所述证券的任何头寸。本文表达的观点是作者的观点,以InvestorPlace.com为准出版指南.

With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com’s writers disclose this fact and warn readers of the risks. Read More: Penny Stocks — How to Profit Without Getting Scammed

除了最罕见的例外,InvestorPlace不会发布关于市值低于1亿美元或每天交易量低于10万股的公司的评论。这是因为这些“廉价股”经常是诈骗艺术家和市场操纵者的游乐场。如果我们确实发布了可能受我们的评论影响的低成交量股票的评论,我们要求 InvestorPlace.com该书的作者披露了这一事实,并警告读者其中的风险。 更多阅读: 便士股票-如何在不上当的情况下获利

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发